Clinical Trial Update: Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant vemurafenib plus cobimetinib for BRAF-mutant melanoma with palpable lymph node metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Cobimetinib (cobimetinib)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: Melanoma | Phase 2 | Status: UNKNOWN